Association Between Pioglitazone and Urothelial Bladder Cancer
Urology, 05/25/2012Barbalat Y et al.
The U.S. Food and Drug Administration and the European Medicines Agency have recently informed the public of a potential impact of pioglitazone (Actos) use on bladder cancer incidence. These recommendations are based on 2 recent large published cohort studies indicating a possible association between pioglitazone use and bladder cancer development.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.